Bristol-Myers Squibb: Hold Rating Amid Moderate Growth and Revenue Variability

In a report released on June 6, Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a price target of $53.00.

Evan Seigerman has given his Hold rating due to a combination of factors related to Bristol-Myers Squibb’s current market performance and projections. The ongoing launch of Cobenfy, a treatment for schizophrenia, has shown moderate growth, but recent data indicates a decline in weekly prescriptions, which fell by 8.6% during a holiday week. Although there is an underlying demand growth when adjusted for the shorter week, the current prescription trends suggest that the revenue for the second quarter of 2025 may fall short of consensus estimates.
Furthermore, Seigerman’s analysis considers several revised assumptions, such as potential inventory build and adjustments in gross-to-net discounts, which add variability to revenue estimates. Despite these challenges, the company’s I/O and hematology divisions continue to generate stable cash flows, and new product launches are progressing, albeit at a slower pace than initially expected. These factors contribute to the assessment that the stock is fairly valued, justifying the Hold rating.

In another report released on June 6, Bank of America Securities also maintained a Hold rating on the stock with a $56.00 price target.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMY in relation to earlier this year.